Collplant Biotechnologies Ltd (CLGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Collplant Biotechnologies Ltd (CLGN) has a cash flow conversion efficiency ratio of -0.309x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.88 Million) by net assets ($9.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Collplant Biotechnologies Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Collplant Biotechnologies Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Collplant Biotechnologies Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Collplant Biotechnologies Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Collplant Biotechnologies Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bio-Gene Technology Ltd
AU:BGT
|
-0.811x |
|
Aldrich Resources Bhd
KLSE:0079
|
-0.587x |
|
The GYM Group PLC
LSE:GYM
|
0.318x |
|
Sentral Mitra Informatika Tbk PT
JK:LUCK
|
-0.026x |
|
Hydrocarbon Dynamics Ltd
AU:HCD
|
-0.355x |
|
Golden Sun Education Group Ltd
NASDAQ:GSUN
|
-0.091x |
|
Megaron SA
WAR:MEG
|
0.020x |
|
Themac Resources Group Limited
V:MAC
|
0.005x |
Annual Cash Flow Conversion Efficiency for Collplant Biotechnologies Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Collplant Biotechnologies Ltd from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see Collplant Biotechnologies Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $13.46 Million | $-14.09 Million | -1.047x | -973.53% |
| 2023-12-31 | $28.34 Million | $-2.76 Million | -0.097x | +77.02% |
| 2022-12-31 | $32.28 Million | $-13.70 Million | -0.424x | -865.55% |
| 2021-12-31 | $45.12 Million | $2.50 Million | 0.055x | +105.58% |
| 2020-12-31 | $4.48 Million | $-4.45 Million | -0.994x | +28.73% |
| 2019-12-31 | $4.09 Million | $-5.70 Million | -1.395x | -445.61% |
| 2018-12-31 | $4.76 Million | $-1.22 Million | -0.256x | +86.54% |
| 2017-12-31 | $2.61 Million | $-4.97 Million | -1.900x | +49.26% |
| 2016-12-31 | $1.34 Million | $-5.02 Million | -3.745x | -152.18% |
| 2015-12-31 | $2.51 Million | $-3.72 Million | -1.485x | -64.13% |
| 2014-12-31 | $3.68 Million | $-3.33 Million | -0.905x | -84.26% |
| 2013-12-31 | $7.78 Million | $-3.82 Million | -0.491x | +46.58% |
| 2012-12-31 | $4.20 Million | $-3.86 Million | -0.919x | -- |
About Collplant Biotechnologies Ltd
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company's products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal … Read more